Nephrocare Health Services financials

·Pharma & HealthChart ›
Latest results Q1 FY27 · Apr–Jun 2026
Revenue
₹282cr 
Net profit
₹32.0cr 
EBITDA margin
22.7% 
EPS
₹3.19 

Quarterly results

Every quarter ›
₹ croreQ1 FY27Year beforeChange
Revenue282——
EBITDA63.9——
EBITDA margin22.7%——
Profit before tax44.6——
Net profit32.0——
EPS₹3.19——

Over time

Q1 FY27 · Apr–Jun 2026latest
Revenue₹282 crNet profit₹32.0 crNet margin11.4%

Amounts on the left scale in ₹ crore; per cent on the right, dashed. L = lakh crore, K = thousand crore. Touch the chart to read any period.

Key numbersby financial year

₹ crore except per share
Tap a line for its trendCurrentlast closeFY26Mar 2026
6,305—
295295
79.779.7
6,091—
999999
227227
22.7%22.7%
136136
76.876.8
7.7%7.7%
₹7.66₹7.66
233233
−119−119
113113
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

NEPHROPLUS₹628.40

Nephrocare Health Services Limited

· Pharma & Health
₹ CrorePeersKRSNAASURAKSHAHEALTHX3BBLACKBIOMcap ₹6,305 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY26
31/03/2026
Current
last close
Market Capitalization—6,305.4
- Cash, Equiv & ST Investments294.5294.5
+ Total Debt79.779.7
Enterprise Value—6,090.5
Revenue998.8998.8
EBITDA227.0227.0
Margin %22.7222.72
EBIT136.3136.3
Net Income76.876.8
Margin %7.697.69
EPS, Adj (current shares)7.667.66
Cash from Operations232.6232.6
Capital Expenditures-119.4-119.4
Free Cash Flow113.2113.2
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Nephrocare Health Services financials and key ratios

Prices at the 29 October 2026 close · figures from the company's filings with NSE

Nephrocare Health Services (NSE: NEPHROPLUS) had a market capitalisation of ₹6,307 crore at the 29 October 2026 close (₹628.55 a share) and a price-to-book ratio of 5.65. In FY26 its consolidated net profit was ₹76.8 crore on revenue of ₹999 crore; in Q1 FY27 (April–June 2026) it was ₹32 crore. Its debt-to-equity ratio was 0.07 on 31 March 2026. Promoters held 58.31% of the shares on 30 September 2026.

Share price used
₹628.55 · 29 October 2026 close
Latest balance sheet
31 March 2026
Shareholding pattern
30 September 2026

Nephrocare Health Services at a glance · consolidated

Market cap
₹6,307 Crat ₹628.55 · 29 Oct close
PE ratio
n/a
Price to book (PB)
5.65book value ₹111.27 a share
Debt to equity
0.07net cash ₹346 Cr
Promoter holding
58.31%−5.5 pts vs 30 Jun 202630 September 2026
Net worth
₹1,116 Cr31 March 2026

Questions

What is the Nephrocare Health Services PB ratio (price to book value)?

Nephrocare Health Services' price-to-book (PB) ratio is 5.65 at the 29 October 2026 close: a market capitalisation of ₹6,307 crore divided by shareholders' equity (book value) of ₹1,116 crore on 31 March 2026. That is a book value of ₹111.27 per share against a share price of ₹628.55.

What is the Nephrocare Health Services net worth?

Nephrocare Health Services' net worth — shareholders' equity in its consolidated balance sheet — was ₹1,116 crore on 31 March 2026. Its market value is a different figure: a market capitalisation of ₹6,307 crore at the 29 October 2026 close.

What is the Nephrocare Health Services shareholding pattern?

On 30 September 2026, Nephrocare Health Services' shares were held by promoters 58.31%, foreign portfolio investors (FII/FPI) 11.73%, domestic institutions (DII) 8.11% (including mutual funds at 3.93%) and retail and other non-institutional investors 21.85%.

What is the Nephrocare Health Services market cap?

Nephrocare Health Services' market capitalisation was ₹6,307 crore at the 29 October 2026 close: 10.03 crore shares at ₹628.55 each.

What is the Nephrocare Health Services debt to equity ratio?

Nephrocare Health Services' debt-to-equity ratio was 0.07 on 31 March 2026: borrowings of ₹79.7 crore against total equity of ₹1,116 crore.

What is the Nephrocare Health Services revenue and profit in FY26?

In FY26 (April 2025–March 2026), Nephrocare Health Services' consolidated net profit was ₹76.8 crore, on revenue from operations of ₹999 crore.

Is Nephrocare Health Services debt free?

No. Nephrocare Health Services had borrowings of ₹79.7 crore on 31 March 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.07. Its cash and current investments were ₹426 crore, so it held net cash of ₹346 crore.

What is the Nephrocare Health Services book value per share?

Nephrocare Health Services' book value per share was ₹111.27 on 31 March 2026: shareholders' equity of ₹1,116 crore divided by the 10.03 crore shares in issue. The share price at the 29 October 2026 close was ₹628.55.

What is the Nephrocare Health Services promoter holding?

Promoters held 58.31% of Nephrocare Health Services on 30 September 2026, down 5.54 percentage points from 63.85% the previous quarter, according to the shareholding pattern filed with NSE.

What is the Nephrocare Health Services EPS?

Nephrocare Health Services' basic earnings per share (EPS) were ₹8.48 in FY26.

What is the Nephrocare Health Services free cash flow?

In FY26, Nephrocare Health Services generated ₹233 crore of cash from operations and spent ₹119 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of ₹113 crore.

What are the Nephrocare Health Services latest quarterly results?

Nephrocare Health Services' latest results are for Q1 FY27 (April–June 2026), filed on 11 August 2026: consolidated net profit ₹32 crore; revenue from operations ₹282 crore.

When are the Nephrocare Health Services next results?

Nephrocare Health Services will announce its Q2 FY27 results (July–September 2026) on Tuesday, 3 November 2026, the date of the board meeting it has notified to the exchanges.

How does Nephrocare Health Services compare with its peers?

On FY26 consolidated figures, against Krsnaa Diagnostics, Suraksha Diagnostic and Health X Platform: Nephrocare Health Services' operating margin of 13.7% is the third highest of the four (Krsnaa Diagnostics 15.7%, Suraksha Diagnostic 17.4%, Health X Platform −4.5%; peer average 9.5%).

How does the Nephrocare Health Services PE ratio compare with its peers?

At the 29 October 2026 closing prices, on FY26 net profit, Nephrocare Health Services' PE ratio is 82.1, the second highest of the four: Krsnaa Diagnostics 15.9, Suraksha Diagnostic 51.7 and Health X Platform 755.3, a peer average of 274.3. Each is the company's market capitalisation at that price divided by its FY26 net profit.

Nephrocare Health Services vs Krsnaa Diagnostics: how do they compare?

In FY26, Nephrocare Health Services earned net profit of ₹76.8 crore on revenue of ₹999 crore, against ₹101 crore on ₹773 crore for Krsnaa Diagnostics. Nephrocare Health Services' operating margin was 13.7% (Krsnaa Diagnostics 15.7%). At the 29 October 2026 close, Nephrocare Health Services' market capitalisation was ₹6,307 crore against ₹1,615 crore for Krsnaa Diagnostics, and its PE ratio on FY26 profit 82.1 against 15.9.

Where do these Nephrocare Health Services figures come from?

From Nephrocare Health Services' own consolidated results, balance sheets and shareholding patterns filed with NSE, and NSE prices (the latest used here: the 29 October 2026 close). Ratios are calculated by Alphave from those filings as each answer describes.

Consolidated figures from the company's filings with NSE; prices are NSE closing prices.